FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2804124474> ?p ?o ?g. }

• W2804124474 abstract "The expression of DNA fragmentation factor 45 (DFF45) and B-cell lymphoma 2 (BCL2) in glands of the normal human endometrium is related to phases of the menstrual cycle and decreases after menopause, whereas the expression of DNA fragmentation factor 40 (DFF40) is stable. Moreover, DF45, BCL2 and DFF40 underexpression has been reported in numerous malignancies, including uterine leiomyosarcomas. In this study, we aimed to investigate DFF45, BCL2 and DFF40 expression in endometrioid and non-endometrioid types of endometrial cancers (ECs). We also evaluated the correlations between DFF45, BCL2 and DFF40 expression levels and clinicopathological parameters and determined the value of these three proteins as prognostic markers of disease-free survival (DFS) and overall survival (OS).Immunohistochemistry was performed to evaluate DFF45, BCL2 and DFF40 expression in 342 cases of ECs. Student's t-test, the Mann-Whitney U-test, and the chi-squared test were used for the statistical analyses as appropriate. The Cox-Mantel test, Cox's proportional hazard model, and relative risk analyses were used to evaluate associations between DFF40, DFF45, and BCL2 expression and clinicopathological characteristics.DFF40 and BCL2, but not DFF45, were significantly underexpressed in non-endometrioid and high-grade endometrioid ECs compared with low- and moderate-grade endometrioid ECs. Women with DFF40- and BCL2-negative tumors had higher risks of disease recurrence, lymph node involvement, lympho-vascular space infiltration, and deep myometrial invasion compared with women with DFF40- and BCL2-positive tumors. Additionally, women with DFF40- and BCL2-negative tumors had significantly lower OS and DFS than women with DFF40- and BCL2-positive tumors. A multivariable analysis of the model, including the clinicopathological characteristics and immunohistochemical results, showed that negative BCL2 expression, lymph node involvement, and high-stage and high-grade disease were independent predictors of OS, whereas negative BCL2 expression, lymph node involvement, and high-stage disease were independent predictors of DFS.Compared with low- and moderate-grade endometrioid ECs, non-endometrioid and high-grade endometrioid ECs showed significant DFF40 and BCL2 underexpression. The absence of DFF40 and BCL2 expression negatively affects DFS and OS. Further prospective studies are warranted to assess the potential utility of DFF40 and BCL2 as targets in the diagnosis or treatment of ECs." @default.
• W2804124474 created "2018-06-01" @default.
• W2804124474 creator A5000101154 @default.
• W2804124474 creator A5000854712 @default.
• W2804124474 creator A5003821766 @default.
• W2804124474 creator A5040053525 @default.
• W2804124474 date "2018-04-13" @default.
• W2804124474 modified "2023-10-17" @default.
• W2804124474 title "Non-endometrioid and high-grade endometrioid endometrial cancers show DNA fragmentation factor 40 (DFF40) and B-cell lymphoma 2 protein (BCL2) underexpression, which predicts disease-free and overall survival, but not DNA fragmentation factor 45 (DFF45) underexpression" @default.
• W2804124474 cites W1465474996 @default.
• W2804124474 cites W1968667761 @default.
• W2804124474 cites W1970980803 @default.
• W2804124474 cites W1974999667 @default.
• W2804124474 cites W1975482936 @default.
• W2804124474 cites W1984283795 @default.
• W2804124474 cites W1995316231 @default.
• W2804124474 cites W1998595310 @default.
• W2804124474 cites W2001404496 @default.
• W2804124474 cites W2002238399 @default.
• W2804124474 cites W2008853487 @default.
• W2804124474 cites W2014623932 @default.
• W2804124474 cites W2015484183 @default.
• W2804124474 cites W2016818279 @default.
• W2804124474 cites W2023032247 @default.
• W2804124474 cites W2024056145 @default.
• W2804124474 cites W2028017661 @default.
• W2804124474 cites W2033521564 @default.
• W2804124474 cites W2041502281 @default.
• W2804124474 cites W2044347713 @default.
• W2804124474 cites W2044869180 @default.
• W2804124474 cites W2050404700 @default.
• W2804124474 cites W2053587401 @default.
• W2804124474 cites W2058614503 @default.
• W2804124474 cites W2094206874 @default.
• W2804124474 cites W2104325778 @default.
• W2804124474 cites W2123895281 @default.
• W2804124474 cites W2137665115 @default.
• W2804124474 cites W2155085560 @default.
• W2804124474 cites W2170352900 @default.
• W2804124474 cites W2184175617 @default.
• W2804124474 cites W2203182086 @default.
• W2804124474 cites W2208094478 @default.
• W2804124474 cites W2297208068 @default.
• W2804124474 cites W2321459591 @default.
• W2804124474 cites W2331722009 @default.
• W2804124474 cites W2339177479 @default.
• W2804124474 cites W2400808877 @default.
• W2804124474 cites W2508500064 @default.
• W2804124474 cites W2526924349 @default.
• W2804124474 cites W2530525054 @default.
• W2804124474 cites W2559453271 @default.
• W2804124474 cites W2566141610 @default.
• W2804124474 cites W2606434554 @default.
• W2804124474 cites W2754520967 @default.
• W2804124474 cites W2755386540 @default.
• W2804124474 cites W2755965065 @default.
• W2804124474 cites W4243413044 @default.
• W2804124474 doi "https://doi.org/10.1186/s12885-018-4333-6" @default.
• W2804124474 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5899339" @default.
• W2804124474 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29653556" @default.
• W2804124474 hasPublicationYear "2018" @default.
• W2804124474 type Work @default.
• W2804124474 sameAs 2804124474 @default.
• W2804124474 citedByCount "8" @default.
• W2804124474 countsByYear W28041244742018 @default.
• W2804124474 countsByYear W28041244742019 @default.
• W2804124474 countsByYear W28041244742020 @default.
• W2804124474 countsByYear W28041244742021 @default.
• W2804124474 countsByYear W28041244742022 @default.
• W2804124474 crossrefType "journal-article" @default.
• W2804124474 hasAuthorship W2804124474A5000101154 @default.
• W2804124474 hasAuthorship W2804124474A5000854712 @default.
• W2804124474 hasAuthorship W2804124474A5003821766 @default.
• W2804124474 hasAuthorship W2804124474A5040053525 @default.
• W2804124474 hasBestOaLocation W28041244741 @default.
• W2804124474 hasConcept C121608353 @default.
• W2804124474 hasConcept C126322002 @default.
• W2804124474 hasConcept C143998085 @default.
• W2804124474 hasConcept C204232928 @default.
• W2804124474 hasConcept C207103383 @default.
• W2804124474 hasConcept C2777088508 @default.
• W2804124474 hasConcept C2780140570 @default.
• W2804124474 hasConcept C29456083 @default.
• W2804124474 hasConcept C44249647 @default.
• W2804124474 hasConcept C71924100 @default.
• W2804124474 hasConcept C90924648 @default.
• W2804124474 hasConceptScore W2804124474C121608353 @default.
• W2804124474 hasConceptScore W2804124474C126322002 @default.
• W2804124474 hasConceptScore W2804124474C143998085 @default.
• W2804124474 hasConceptScore W2804124474C204232928 @default.
• W2804124474 hasConceptScore W2804124474C207103383 @default.
• W2804124474 hasConceptScore W2804124474C2777088508 @default.
• W2804124474 hasConceptScore W2804124474C2780140570 @default.
• W2804124474 hasConceptScore W2804124474C29456083 @default.
• W2804124474 hasConceptScore W2804124474C44249647 @default.
• W2804124474 hasConceptScore W2804124474C71924100 @default.
• W2804124474 hasConceptScore W2804124474C90924648 @default.
• W2804124474 hasIssue "1" @default.
• W2804124474 hasLocation W28041244741 @default.
• W2804124474 hasLocation W28041244742 @default.

• next